Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/90866
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPitman, M.en
dc.contributor.authorPowell, J.en
dc.contributor.authorCoolen, C.en
dc.contributor.authorMoretti, P.en
dc.contributor.authorZebol, J.en
dc.contributor.authorPham, D.en
dc.contributor.authorFinnie, J.en
dc.contributor.authorDon, A.en
dc.contributor.authorEbert, L.en
dc.contributor.authorBonder, C.en
dc.contributor.authorGliddon, B.en
dc.contributor.authorPitson, S.en
dc.date.issued2015en
dc.identifier.citationOncotarget, 2015; 6(9):7065-7083en
dc.identifier.issn1949-2553en
dc.identifier.issn1949-2553en
dc.identifier.urihttp://hdl.handle.net/2440/90866-
dc.description.abstractThe dynamic balance of cellular sphingolipids, the sphingolipid rheostat, is an important determinant of cell fate, and is commonly deregulated in cancer. Sphingosine 1-phosphate is a signaling molecule with anti-apoptotic, pro-proliferative and pro-angiogenic effects, while conversely, ceramide and sphingosine are pro-apoptotic. The sphingosine kinases (SKs) are key regulators of this sphingolipid rheostat, and are attractive targets for anti-cancer therapy. Here we report a first-in-class ATP-binding site-directed small molecule SK inhibitor, MP-A08, discovered using an approach of structural homology modelling of the ATP-binding site of SK1 and in silico docking with small molecule libraries. MP-A08 is a highly selective ATP competitive SK inhibitor that targets both SK1 and SK2. MP-A08 blocks pro-proliferative signalling pathways, induces mitochondrial-associated apoptosis in a SK-dependent manner, and reduces the growth of human lung adenocarcinoma tumours in a mouse xenograft model by both inducing tumour cell apoptosis and inhibiting tumour angiogenesis. Thus, this selective ATP competitive SK inhibitor provides a promising candidate for potential development as an anti-cancer therapy, and also, due to its different mode of inhibition to other known SK inhibitors, both validates the SKs as targets for anti-cancer therapy, and represents an important experimental tool to study these enzymes.en
dc.description.statementofresponsibilityMelissa R. Pitman, Jason A. Powell, Carl Coolen, Paul A.B. Moretti, Julia R. Zebol, Duyen H. Pham, John W. Finnie, Anthony S. Don, Lisa M. Ebert, Claudine S. Bonder, Briony L. Gliddon, Stuart M. Pitsonen
dc.language.isoenen
dc.publisherImpact Journalsen
dc.rightsAll site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. PII: 3178en
dc.subjectapoptosis; in silico docking; molecular modeling; small molecule inhibitor; sphingosine kinaseen
dc.titleA selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer propertiesen
dc.typeJournal articleen
dc.identifier.rmid0030026677en
dc.identifier.doi10.18632/oncotarget.3178en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1042589en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1004695en
dc.identifier.pubid178447-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS08en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidPham, D. [0000-0003-0664-4133]en
dc.identifier.orcidEbert, L. [0000-0002-8041-9666]en
dc.identifier.orcidBonder, C. [0000-0001-9875-967X]en
dc.identifier.orcidPitson, S. [0000-0002-9527-2740]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_90866.pdfPublished version9.04 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.